On September 17, 2026, BlackRock, Inc. acquired 10.94 million shares of CSPC Pharma (01093) by way of taking a security interest in shares via an off-exchange transaction (nature of consideration: non-cash assets).
Prior to the acquisition, BlackRock, Inc.'s long position in CSPC Pharma was 565.29 million shares, representing 4.91%; following the acquisition, the holding changed to 576.23 million shares, with the long position ratio rising to 5.0%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments